Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xtandi
Pharma
Sun-Organon, Astellas, BeOne—Fierce Pharma Asia
Sun will buy Organon for $11.75 billion. Astellas projects Xtandi sales declines in FY2026. BeOne has eyes on a PD-1xCTLA-4xVEGF trispecific antibody.
Angus Liu
May 1, 2026 8:43am
Astellas projects Xtandi decline but overall growth in FY2026
Apr 27, 2026 11:30am
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
Mar 19, 2026 6:45am
Astellas, Takeda, Chugai and more—Fierce Pharma Asia
Jan 23, 2026 9:05am
Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears
Jan 15, 2026 10:42am
Lilly-Innovent, Dizal, bispecific ADC—Fierce Pharma Asia
Jul 10, 2025 5:20pm
